Call Us: 1.800.873.5297

By

New Research Suggests that Testosterone Drugs Linked to Increased Risk of Heart Attacks, Strokes

Testosterone is used in men and boys to treat conditions caused by a lack of this hormone. Use of testosterone drugs has increased over the past decade, particularly in the United States, with dramatic shifts from injections to gels. Sales of testosterone gels and creams have dramatically increased despite the fact that long-term effects associated […]

By

EMA Investigates whether Emergency Contraceptives are Effective for Overweight Women

The European Medicines Agency (EMA), the regulatory authority in Europe similar to the United States Food and Drug Administration (FDA), is investigating whether emergency contraceptives, known as the “morning-after pill”, are effective in women who are overweight or obese. On January 24, 2014, the EMA issued a statement indicating that they have “started a review […]

By

Actos® Lawsuit Update: First Actos® Trial in Federal Court Begins

The first trial in the Multidistrict Litigation In re: Actos® (Pioglitazone) Products Liability Litigation, MDL 2299, begins today, January 27, 2014 with opening statements expected to occur on February 3, 2014. The Actos® Multidistrict Litigation (MDL 2299) is currently pending in the United States District Court for the Western District of Louisiana before The Honorable […]

By

FDA Warns of Dangers associated with Excessive Use of Laxative Products

On January 8, 2014, the FDA issued a Safety Announcement “warning that using more than one dose in 24 hours of over-the-counter sodium phosphate drugs to treat constipation can cause rare but serious harm to the kidneys and heart, and even death.” The sodium phosphate drug products at issue are marketed under the brand-name Fleet, […]

By

FDA Issues Class I Recall of Certain Ventilators due to Software Problem

On December 16, 2013, the FDA issued a Class I Recall of the Covidien Puritan Bennett™ 840 Series Ventilator due to a software problem. As defined by the FDA, “Class I Recalls are the most serious type of recall and involve situations in which there is reasonable probability that use of these products will cause […]

By

FDA Restricts Drugs with High Doses of Acetaminophen

In January 2011, the FDA requested that manufacturers limit drug products containing acetaminophen to no more than 325 mg in each tablet or capsule by January 14, 2014. FDA held true to the request and will soon withdraw approval for any medications containing more than 325 mg of acetaminophen. On January 14, 2014, the FDA issued […]

By

Transvaginal Mesh MDL Lawsuit Update: C.R. Bard Denied Request to Exclude Certain Documents at Trial

Law 360 reports that The Honorable Judge Joseph Goodwin, who presides over the C.R. Bard Multidistrict Litigation (MDL) pending in the Southern District of West Virginia, has denied C.R. Bard’s motion requesting the exclusion of an employee’s proposed changes to vaginal mesh products as evidence based on the finding that they touched on the issue […]

By

Schlichter, Bogard & Denton, LLP Attorney Kristine Kraft Featured in Huffington Post Article on Dangers of NuvaRing

A recent exposé by The Huffington Post, titled Side Effects May Include Death: The Story of the Biggest Advance in Birth Control Since the Pill, discusses the dangers allegedly posed by NuvaRing®, one of the most popular forms of birth control in the world. More than 2,000 cases are currently pending in the United States […]

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.